Tags

Type your tag names separated by a space and hit enter

Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
Eur Neurol. 2008; 60(2):57-66.EN

Abstract

Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson's disease but its long-term use is associated with the development of dyskinesias. Although the pathogenic processes behind the development of levodopa-induced dyskinesias are still being elucidated, it appears that chronic administration of this short-lived agent results in nonphysiologic pulsatile stimulation of striatal neurons and abnormal firing patterns in the basal ganglia. Dyskinesias have been associated with decreased quality of life, and a number of methodologies to evaluate severity of dyskinesias are now available. Strategies to avoid, reduce, or eliminate dyskinesias include providing more continuous dopaminergic stimulation, administering an antidyskinetic agent, and surgery. Several new compounds that may provide an antidyskinetic effect are also under investigation.

Authors+Show Affiliations

Department of Neurology, Texas A&M Health Sciences Center, Scott and White National Parkinson Foundation Plummer Movement Disorders Center, Temple, TX, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18480609

Citation

Encarnacion, Elmyra V., and Robert A. Hauser. "Levodopa-induced Dyskinesias in Parkinson's Disease: Etiology, Impact On Quality of Life, and Treatments." European Neurology, vol. 60, no. 2, 2008, pp. 57-66.
Encarnacion EV, Hauser RA. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol. 2008;60(2):57-66.
Encarnacion, E. V., & Hauser, R. A. (2008). Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. European Neurology, 60(2), 57-66. https://doi.org/10.1159/000131893
Encarnacion EV, Hauser RA. Levodopa-induced Dyskinesias in Parkinson's Disease: Etiology, Impact On Quality of Life, and Treatments. Eur Neurol. 2008;60(2):57-66. PubMed PMID: 18480609.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. AU - Encarnacion,Elmyra V, AU - Hauser,Robert A, Y1 - 2008/05/15/ PY - 2007/10/10/received PY - 2007/12/08/accepted PY - 2008/5/16/pubmed PY - 2008/10/7/medline PY - 2008/5/16/entrez SP - 57 EP - 66 JF - European neurology JO - Eur Neurol VL - 60 IS - 2 N2 - Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson's disease but its long-term use is associated with the development of dyskinesias. Although the pathogenic processes behind the development of levodopa-induced dyskinesias are still being elucidated, it appears that chronic administration of this short-lived agent results in nonphysiologic pulsatile stimulation of striatal neurons and abnormal firing patterns in the basal ganglia. Dyskinesias have been associated with decreased quality of life, and a number of methodologies to evaluate severity of dyskinesias are now available. Strategies to avoid, reduce, or eliminate dyskinesias include providing more continuous dopaminergic stimulation, administering an antidyskinetic agent, and surgery. Several new compounds that may provide an antidyskinetic effect are also under investigation. SN - 1421-9913 UR - https://www.unboundmedicine.com/medline/citation/18480609/Levodopa_induced_dyskinesias_in_Parkinson's_disease:_etiology_impact_on_quality_of_life_and_treatments_ L2 - https://www.karger.com?DOI=10.1159/000131893 DB - PRIME DP - Unbound Medicine ER -